Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Kyverna Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get KYTX alerts

About Marc Grasso

Marc Grasso is recorded as CFO at Kyverna Therapeutics, Inc. (KYTX) and CFO at Alector, Inc. (ALEC) since February 7, 2022. The newest filing on record that lists Marc Grasso as CFO at Kyverna Therapeutics, Inc. (KYTX) is dated April 13, 2026. Earlier roles on record: CFO at Kura Oncology, Inc. (KURA) until February 4, 2022. Kyverna Therapeutics, Inc. reported in an 8-K filed May 18, 2026 that Marc Grasso resigned as principal financial officer, effective May 18, 2026. The same filing states: “Dr. Grasso’s transition is not due to any disagreement with the Company relating to any of the Company’s operations, policies or practices or on any matter relating to the Company’s financial reporting.” Kyverna Therapeutics, Inc. reported in an 8-K filed May 18, 2026 that Marc Grasso resigned as principal accounting officer, effective May 18, 2026. The same filing states: “Dr. Grasso’s transition is not due to any disagreement with the Company relating to any of the Company’s operations, policies or practices or on any matter relating to the Company’s financial reporting.” Kyverna Therapeutics, Inc. reported in an 8-K filed June 30, 2025 that Marc Grasso was appointed Chief Financial Officer, effective June 30, 2025. Equibles holds 6 filed executive changes naming Marc Grasso; each is listed under recent activity with its source filing. The proxy statement of Kyverna Therapeutics, Inc. reports total compensation of $1,663,536 for Marc Grasso in fiscal 2025, including a base salary of $256,961. Disclosed compensation is on record for 8 fiscal years. Marc Grasso has spoken on 7 earnings calls across 1 company, most recently for Kura Oncology, Inc. on November 4, 2021. Alector, Inc. is classified in the Biotechnology industry within the Healthcare sector. Kyverna Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Marc Grasso spoke on are classified in the Healthcare sector. Other leadership on record at Alector, Inc. includes Arnon Rosenthal (CEO and Board Member), Marc Grasso, M.D. (CFO), Neil Berkley (CFO) and 7 others.

“Effective upon the appointment of Mr. Martini as the Company’s Chief Financial Officer, Marc Grasso, M.D. ceased serving as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer.”
“Dr. Grasso’s transition is not due to any disagreement with the Company relating to any of the Company’s operations, policies or practices or on any matter relating to the Company’s financial reporting.”
Kyverna Therapeutics, Inc. Form 8-K, filed May 18, 2026 · Read the filing
“Effective upon the appointment of Mr. Martini as the Company’s Chief Financial Officer, Marc Grasso, M.D. ceased serving as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer.”
“Dr. Grasso’s transition is not due to any disagreement with the Company relating to any of the Company’s operations, policies or practices or on any matter relating to the Company’s financial reporting.”
Kyverna Therapeutics, Inc. Form 8-K, filed May 18, 2026 · Read the filing

Marc Grasso on recent calls

“I'll provide a brief overview of our financial results for the third quarter 2021, along with reiterating our guidance for the full year 2021. I invite you to review our 10-Q filed today for a more detailed discussion.”
CFO, Kura Oncology, Inc. Q3 FY2021 Earnings Call ·
“I'll provide a brief overview of our financial results for the second quarter of 2021, along with guidance for the full year 2021. I invite you to review our 10-Q filed today for a more detailed discussion.”
CFO, Kura Oncology, Inc. Q2 FY2021 Earnings Call ·
“I'll provide a brief overview of our financial results here on the call and invite you to review our 10-Q filed today for a more detailed discussion. Research and development expenses for the first quarter of 2021 were $20.3 million compared to $12.6 million for the first quarter of 2020.”
CFO, Kura Oncology, Inc. Q1 FY2021 Earnings Call ·
“I'll provide a brief overview of our financial results here on the call and invite you to review our 10-K filed today for a more detailed discussion. Research and development expenses for the fourth quarter of 2020 were $17.5 million, compared to $13.5 million for the fourth quarter of 2019.”
CFO, Kura Oncology, Inc. Q4 FY2020 Earnings Call ·
“I'll provide a brief overview of our financial results here on the call and invite you to review our 10-Q filed today for a more detailed discussion. Research and development expenses for the third quarter of 2020 were $16.6 million compared to $12.5 million for the third quarter of 2019.”
CFO, Kura Oncology, Inc. Q3 FY2020 Earnings Call ·

Affiliation history

Company network

Current role

Biotechnology · Healthcare

CFO

2022-02-07–present

Leadership on record at Alector, Inc.

Leadership on record at Kyverna Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Kyverna Therapeutics, Inc. (KYTX) $256,961 $1,663,536
2024 Alector, Inc. (ALEC) $514,777 $1,687,869
2023 Alector, Inc. (ALEC) $496,800 $1,715,846
2022 Kura Oncology, Inc. (KURA) $45,608 $1,694,717
2022 Alector, Inc. (ALEC) $432,923 $6,011,780
2021 Kura Oncology, Inc. (KURA) $446,300 $4,356,608
2020 Kura Oncology, Inc. (KURA) $415,000 $1,589,108
2019 Kura Oncology, Inc. (KURA) $387,750 $2,112,282
2018 Kura Oncology, Inc. (KURA) $136,876 $3,634,267

Recent activity

Show 1 earlier activities